Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
58 studies found for:    Open Studies | "Waldenstrom Macroglobulinemia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Ixazomib;   Drug: Dexamethasone;   Drug: Rituximab
2 Recruiting Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Ibrutinib
3 Recruiting Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: ABT199
4 Recruiting Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Dexamethasone, Rituximab, Cyclophosphamide;   Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
5 Recruiting Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Other: autologous stem cell transplantation;   Other: conventional chemotherapy
6 Recruiting The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
7 Recruiting Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Bortezomib-Rituximab-Bendamustine
8 Not yet recruiting Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Obinutuzumab;   Drug: Idelalisib
9 Recruiting Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Intervention: Biological: Blood or bone marrow samples
10 Recruiting The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
Condition: Waldenström Macroglobulinemia
Intervention: Drug: Thalidomide
11 Recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
12 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
13 Recruiting PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
Condition: Treatment
Interventions: Drug: rituximab /Dexamethasone/cyclophosphamide;   Drug: Velcade/Dexamethasone/cyclophosphamide
14 Not yet recruiting Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom's Macroglobulinemia;   Mantle Zone Lymphoma Refractory/Recurrent;   Follicle Centre Lymphoma Diffuse;   Diffuse Large B Cell Lymphoma
Intervention: Drug: CT-1530
15 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia;   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia;   Splenic Marginal Zone Lymphoma
Intervention:
16 Recruiting BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Conditions: B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
Interventions: Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
17 Recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Conditions: Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
Intervention:
18 Recruiting Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
19 Not yet recruiting Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mediastinal Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
20 Recruiting Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.